Platelets as drivers of ischemia/reperfusion injury after stroke. by Shaik, Noor F et al.
Thomas Jefferson University 
Jefferson Digital Commons 
Cardeza Foundation for Hematologic Research Sidney Kimmel Medical College 
3-9-2021 
Platelets as drivers of ischemia/reperfusion injury after stroke. 
Noor F Shaik 
Raymond F Regan 
Ulhas P Naik 
Follow this and additional works at: https://jdc.jefferson.edu/cardeza_foundation 
 Part of the Hematology Commons 
Let us know how access to this document benefits you 
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital 
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is 
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections 
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested 
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been 
accepted for inclusion in Cardeza Foundation for Hematologic Research by an authorized administrator of the 
Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu. 
REVIEW ARTICLE
Platelets as drivers of ischemia/reperfusion injury after stroke
Noor F. Shaik,1 Raymond F. Regan,2 and Ulhas P. Naik1
1Cardeza Foundation for Hematologic Research, Thomas Jefferson University, Philadelphia, PA; and 2Department of Emergency Medicine, School of Medicine, University of
Maryland, Baltimore, MD
Ischemic stroke is a leading cause of morbidity and mortality worldwide and, despite
reperfusion either via thrombolysis or thrombectomy, stroke patients often suffer from
lifelong disabilities. These persistent neurological deficits may be improved by treating the
ischemia/reperfusion (I/R) injury that occurs following ischemic stroke. There are currently
no approved therapies to treat I/R injury, and thus it is imperative to find new targets to
decrease the burden of ischemic stroke and related diseases. Platelets, cell fragments from
megakaryocytes, are primarily known for their role in hemostasis. More recently,
investigators have studied the nonhemostatic role of platelets in inflammatory pathologies,
such as I/R injury after ischemic stroke. In this review,we seek to provide an overviewof how
I/R can lead to platelet activation and how activated platelets, in turn, can exacerbate I/R
injury after stroke. We will also discuss potential mechanisms by which platelets may
ameliorate I/R injury.
Introduction
“It is impossible to cure a severe attack of [stroke], and difficult to cure a mild one.” —Hippocrates1
Strokes are a leading cause of death globally and the leading cause of preventable, long-term disability in
the United States.2 Over 80% of strokes are primarily ischemic, in which clots occlude blood flow to
downstream brain tissue.3 Several clinical trials have established that prompt removal of the clot, either
pharmacologically via recombinant tissue plasminogen activator (rt-PA) or by thrombectomy, is
beneficial for patients. The 1995 National Institute of Neurological Disorders and Stroke (NINDS) rt-PA
Stroke Study was the first to demonstrate that compared with placebo, administration of rt-PA within
3 hours after symptom onset improves functional outcomes in patients 3 months after ischemic stroke.4
This trial also highlighted that, although the risk for hemorrhagic transformation (which is bleeding into
the brain after clot removal) is 6.4% in patients treated with rt-PA compared with 0.6% of placebo-
treated patients, the 90-day mortality is comparable between both groups.4
The time window was extended from 3 hours to 4.5 hours following the publication of the 2008
European Cooperative Acute Stroke Study III (ECASS III).5 However, considerations of time from stroke
onset and risk of hemorrhage have limited the actual number of ischemic stroke patients treated with rt-
PA to ,10%.5-7 An alternative or complementary treatment to rt-PA in patients with occlusion of
proximal large vessels is mechanical thrombectomy, which was found to be clinically beneficial when
performed within 6 hours after symptom onset in the Multicenter Randomized Clinical Trial of
Endovascular Treatment for Acute. Ischemic Stroke in The Netherlands (MR CLEAN).8 This time
window was further expanded by results of the Diffusion Weighted Imaging or Computerized
Tomography Perfusion Assessment with Clinical Mismatch in the Triage of Wake Up and Late
Presenting Strokes Undergoing Neurointervention (DAWN) trial, which assessed patients with clinical
presentations that were disproportionately more severe than the infarction volume detected on
emergent imaging, indicating significant tissue at risk that could be salvaged by reperfusion. In this group,
Submitted 7 July 2020; accepted 1 February 2021; published online 9 March 2021.
DOI 10.1182/bloodadvances.2020002888.
Requests for data may be e-mailed to the corresponding author, Ulhas P. Naik, at
ulhas.naik@jefferson.edu.
© 2021 by The American Society of Hematology




 http://ashpublications.org/bloodadvances/article-pdf/5/5/1576/1802248/advancesadv2020002888.pdf by guest on 29 April 2021
thrombectomy was associated with better functional outcomes
3 months after the stroke when performed up to 24 hours after
symptom onset.9
Although it is essential to resupply oxygen and nutrients to injured
tissue, subsequent ischemia/reperfusion (I/R) injury can continue
propagating cell injury via generation of reactive oxygen species
(ROS) and other metabolites that drive inflammation.3,10,11 For
instance, although the DAWN trial showed a clear clinical benefit in
terms of functional outcome and independence 90 days after
stroke/thrombectomy compared with standard care, more than half
of the patient cohort (51%) still showed persistent functional
deficits and lack of functional independence.9 And, although NINDS
showed an improvement in functional outcome after treatment with
rt-PA, the mortality rates between the placebo and rt-PA groups are
similar, highlighting the need for treatments to improve survival after
stroke.4 Therefore, although reperfusion is essential to prevent
further cell death and functional decline, the full clinical benefit of
reperfusion may not be realized without attention to and treatment
of I/R injury. The development of effective reperfusion strategies
now presents an urgent need for novel therapies to minimize these
secondary injury cascades. Unfortunately, there are presently no
approved treatments for I/R injury following strokes.
Antiplatelet therapy with aspirin and/or clopidogrel is already the
standard of care for secondary prevention of stroke, supported by
several multicenter trials.12 Conversely, antithrombotic therapies not
targeting platelets, including anticoagulation with warfarin, heparin,
and low-molecular-weight heparin, are effective only in patients with
atrial fibrillation, where they act to prevent atrial clot formation.13
Recently, there has been increasing interest in the role of platelets as
drivers of inflammation, providing a mechanistic link with I/R injury and
potentially identifying novel therapeutic targets.14,15
In this review, we will first discuss the potential mechanisms of
I/R-mediated platelet activation and how platelets can worsen
reperfusion injury after strokes. Because platelets are renowned for
their role in preventing hemorrhage by creating a platelet plug after
endothelial injury, we will also discuss potential platelet-based
strategies to prevent hemorrhagic transformation. Finally, because
the focus of this review is on I/R injury following stroke, emphasis is
placed on the filament-induced transient middle cerebral artery
(MCA) occlusion (tMCAO) model, which mimics the focal ischemia
seen in most strokes and is ideal for studying both reperfusion injury
and the potential for hemorrhagic transformation.16 In this model,
the MCA of rodents is occluded unilaterally by inserting a silicon-
coated monofilament from the common or external carotid artery to
the branch point where the MCA meets the Circle of Willis, causing
ischemia by physically preventing blood from entering the MCA;
after typically 1 hour, it is removed to allow reperfusion of the brain.
I/R-induced platelet activation
In the following section, we present potential agonists that could
activate platelets after I/R (Table 1).There are many others that
could play a role in platelet-mediated I/R injury (such as glutamate),
but the evidence for these is speculative at this point and they are
not discussed here.
I/R-generated ROS and its effect on platelets
One of the first phenomena that occurs in I/R injury is the “oxygen
paradox,” whereby ischemia leads to cellular energy failure and
a build-up of purinergic degradation compounds, namely hypoxan-
thine. Then, as blood and oxygen flow back to the region during
reperfusion, oxygen fuels xanthine oxidase–mediated conversion of
hypoxanthine to xanthine and uric acid, releasing superoxide anion
in the process.11 Other sources of oxidative stress include
leukocyte reduced nicotinamide adenine dinucleotide phosphate
oxidases and electron leak from mitochondria, all of which can
contribute to increased ROS following stroke.11 Thus, affected
tissues experience an immense amount of oxidative stress caused
by the superoxide anion, its byproduct (hydrogen peroxide), and
other ROS generated in this process. Furthermore, the brain is very
sensitive to ischemia due to its having the highest metabolic activity
per unit weight of any organ and lower levels of protective
antioxidant enzymes that help mitigate injury from ROS.10,11 This
leads to an even higher amount of oxidative stress in ischemic
strokes compared with I/R in other organs. This I/R-generated ROS
can enhance platelet activity as described in the next paragraph.
One of the primary mechanisms for ROS-enhanced platelet activity is
quenching of the platelet inhibitor, nitric oxide (NO), by extracellular
ROS. NO is synthesized by many cells including platelets, endothelial
cells (ECs), and macrophages.17 How NO potently inhibits platelet
adhesion and aggregation to the endothelium is extensively reviewed
by others, but in short, NO leads to an increase in cyclic guanosine
monophosphate and protein kinase G activation inside platelets, which
downregulates calcium signaling and subsequent platelet activation,
adhesion, and aggregation.17,18 Furthermore, high levels of cyclic
guanosine monophosphate in platelets at the edge of a thrombus
promote thrombus dissolution in high-shear conditions (such as those
in carotid/cerebral vessels), thus preventing complete vessel occlu-
sion.19 In addition, NO is particularly important for maintaining a healthy
endothelium as decreased NO is associated with increased platelet/
leukocyte adhesion and vasoconstriction, both of which can lead to
capillary no-reflow after reperfusion, worsening the initial ischemic
injury.20 Hence, the burst of ROS generated after I/R decreases the
bioavailability of NO and subsequently decreases the threshold for
platelet activation and thrombus propagation.
Role of VWF axis in I/R injury
von Willebrand factor (VWF) is a glycoprotein (GP) that is
synthesized by ECs and stored in/released from their Weibel-
Palade bodies; VWF mediates platelet adhesion and subsequent
Table 1. List of agonists released after ischemic stroke/reperfusion










ADAMTS13, a disintegrin-like and metalloprotease with thrombospondin type 1 motif
number 13; ADP, adenosine 59-diphosphate; HMGB1, high-mobility group box-1; S1P,
sphingosine-1-phosphate; VWF, von Willebrand factor.
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activation by binding GPIb of the platelet-specific GP Ib-IX-V
complex. Both during hypoxia and subsequent reoxygenation, ECs
display a pronounced release of VWF in media, just as would occur
during I/R.21 In addition to hypoxia, uric acid can also stimulate
Weibel-Palade body exocytosis in ECs.22 Platelets are an alternate
source of VWF because megakaryocytes also synthesize VWF and
bequeath it to platelets in their a granules. Although VWF is also
released by degranulated platelets, in this section, we are focusing
on how VWF released from I/R-injured endothelium can activate
platelets. Regardless of the source, VWF is a major player in the
progression of I/R injury (Figure 1).23,24
Several groups subsequently pursued the role of VWF in the
context of ischemic stroke. Kleinschnitz et al observed that
blockade of the VWF receptor GPIb with Fab fragments of the
monoclonal antibody p0p/B to GPIba attenuated tMCAO-induced
I/R injury by decreasing both infarct size and neurological deficits.25
Remarkably, this protection persisted even when the Fab fragments
to GPIb were injected immediately prior to reperfusion, suggesting
a clinically relevant time window.25 Consistent with these observa-
tions, 2 groups independently reported that VWF knockout mice
were also significantly protected from cerebral I/R injury.26,27 By
tracking the progression of the infarct and cerebral blood flow using
ultra-high-field magnetic resonance imaging in control mice and
those treated with the Fab to GPIb at 2 and 24 hours after tMCAO,
that is, 1 and 23 hours after reperfusion, Pham et al saw that GPIb
blockade increased cerebral blood flow and sustained reperfu-
sion.28 This implies that microthrombi and no-reflow may play
a major role in VWF-mediated infarct progression.
Consequently, GPIb blockade was shown to indeed reduce
thrombus burden and the amount of occluded cerebral micro-
vessels.29 Furthermore, leukocyte infiltration was also decreased in
the treated mice, indicating that VWF is also important for platelet-
mediated leukocyte recruitment and subsequent inflammation.
Platelet interactions with leukocytes, particularly neutrophils, are
known to be key for platelet-mediated I/R injury and have been
extensively detailed in the cited excellent reviews, and we refer the
reader to these for further information.30-32 In short, activated
platelets secrete granules and release proinflammatory cytokines
that stimulate ECs and leukocytes, leading to edema and
heightened neutrophil recruitment and extravasation to the injured
tissue.33-39 When recruited to the site of I/R, neutrophils amplify I/R
injury by releasing a burst of ROS as they phagocytose cellular
debris.40-43 Platelets also form complexes with neutrophils known
as platelet-neutrophil aggregates (PNAs), which, along with
constriction of capillary pericytes, are implicated in capillary no-
reflow.44-46 Of note, targeting the A1 domain of VWF in particular
(which forms the binding site for GP1b), was recently found to
confer protection by decreasing leukocyte recruitment after
stroke.47 In addition to Fab-mediated GPIb inhibition, a separate
group also observed that pharmacologically targeting GPIb with
anfibatide similarly protects from stroke-mediated I/R injury.48
Moreover, anfibatide treatment reduced vascular permeability and
tissue edema.49
Another protein in the GPIb-VWF–signaling axis is a disintegrin-like
and metalloprotease with thrombospondin type 1 motif number 13
(ADAMTS13). VWF is secreted as large multimers, known as ultra-
large VWF, which are subsequently cleaved into smaller fragments
by ADAMTS13. Uncleaved ultra-large VWF is highly thrombogenic,
and the absence of ADAMTS13 increases cerebral infarction after
tMCAO.27,50 Infusion of a high dose of recombinant human
ADAMTS13 into wild-type (WT) mice reduced infarct size and
improved neurological outcomes.27 Mechanistically, absence of
ADAMTS13 exacerbates I/R injury by not only leading to a greater
accumulation of platelet-VWF-leukocyte aggregates, but also
increasing leukocyte infiltration.50 Further investigation revealed
that ADAMTS13 knockout mice also had elevated levels of high-
mobility group box-1 (HMGB1), which is a potential platelet agonist
in its own right (discussed in the next paragraph).51 As with VWF,
lack of ADAMTS13 is implicated in both microvascular obstruction
and inflammation after stroke.52 Thus, not only is GPIb inhibition an
attractive target for the amelioration of I/R injury after stroke, but
ADAMTS13 infusion is also an exciting alternative because both
protect from I/R injury without leading to hemorrhage.27
Proplatelet agonists like DAMPs are released by
I/R-injured cells
I/R injury causes damaged cells to release a plethora of molecules,
including damage-associated molecular patterns (DAMPs) that
induce inflammation.11 One such DAMP is HMGB1, a nonhistone
DNA-binding protein, which is rapidly released into the extracellular
space following cerebral ischemia and, as aforementioned, also





















Figure 1. Summary of platelet functions that can affect
I/R injury. Following I/R, activated platelets can promote I/R
injury by interacting with VWF, binding to exposed subendothe-
lial collagen, secreting granules and recruiting/activating leuko-
cytes, especially neutrophils, exposing phosphatidylserine (PS;
which enhances thrombin generation), and releasing platelet
microparticles (PMPs; which can affect other cells by delivery
of microRNAs) to enhance tissue death. PNA, platelet-
neutrophil aggregate.
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context of platelets, HMGB1 can enhance agonist-induced platelet
activation, granule secretion, and thrombus formation via interaction
with platelet Toll-like receptor 4.54 Intriguingly, platelet activation
also resulted in pronounced translocation of HMGB1 from the
cytosol to the platelet surface.55 Thus, it is possible that platelet
HMGB1 may further I/R injury as well. Another DAMP released by
necrotic cells is adenosine 59-diphosphate (ADP), which can bind
to platelet receptors P2Y12 and P2Y1. Inhibition of P2Y12 either
genetically or pharmacologically protected mice from injury after
tMCAO/reperfusion.56-58
Sphingosine-1-phosphate (S1P) is another I/R-associated product
that has been implicated in inflammation, and the utility of blocking
the sphingolipid pathway in stroke has recently been summarized.59
Red blood cells and the vascular endothelium can secrete S1P, and
S1P can also activate platelets.60-62 Furthermore, S1P is released
by activated platelets and can act as a secondary agonist, and this
platelet-released S1P exerts paracrine effects on ECs.62 The role of
platelet-derived S1P in inflammation has been reviewed.63 Blocking
S1PR2 through the inhibitor JTE-013 reduced cerebral I/R injury.64
Perhaps some of the protective effect of JTE-013 is due to its
inhibition of S1P-induced platelet activation, and because ischemic
stroke increases S1P levels; this is a potential topic for future study
to tease out the contribution of S1P-induced platelet activation on
infarct size and functional outcomes.65
Platelet activation following interaction with ECs
and collagen
In addition to agonist-induced platelet activation, platelets can also bind
to stimulated endothelium just minutes after reperfusion via cell-
adhesion molecules (ICAM, VCAM), CD40/CD40L interactions, EC
aVb3to platelet aIIbb3 via fibrinogen, and E-selectin/P-selectin
upregulated on I/R-injured ECs.32,35 Others have reviewed these
mechanisms, and we refer the reader to these excellent reviews for
details.15,32 Of note, platelet adhesion to the I/R-stimulated endothe-
lium was particularly affected by blocking P-selectin interactions
compared with ICAM/aIIbb3 interactions after tMCAO.
39 Although
platelets can directly bind to the I/R-stimulated endothelium, electron
microscopy demonstrated that reperfusion worsened endothelial
denudation in the rat brain as compared with ischemia alone.66
Because endothelial denudation exposes the subendothelial matrix,
this means that, after I/R, platelets also come in contact with one of
their most potent endogenous agonists, collagen (Figure 1). As such,
targeting the platelet collagen receptor GPVI with Fab fragments of
JAQ1 monoclonal antibody after stroke decreased infarct volume.25
Finally, thrombin is a serine protease that not only potently activates
platelets but also induces endothelial permeability.34 Plasma samples
from ischemic stroke patients revealed an increased level of thrombin-
antithrombin complexes (a measure of thrombin activation) after
atherothrombotic infarcts.67 Along those lines, lower concentrations of
thrombin-antithrombin correlated with better recanalization following rt-
PA treatment in patients.68 Studies in mice showed that both interfering
with the coagulation cascade (by targeting tissue factor, factor XII, or
kallikrein) and directly inhibiting thrombin (via argatroban) decreased
infarct size after ischemic stroke.69-72
Platelet-mediated I/R injury
As depicted in Figure 1, the next section will focus on how various
platelet-mediated activities can affect I/R injury; namely, we will look
at integrin aIIbb3, platelet-secreted products, phosphatidylserine
(PS) exposure, and microparticle (MP) formation and how these
may impact tissue death after ischemic stroke/reperfusion.
aIIbb3 inhibition has little effect on I/R injury
Platelet integrin aIIbb3 is not only essential for platelet aggregation,
but it also mediates PNA formation (via neutrophil aMb2) and
facilitates leukocyte recruitment and platelet-EC interaction
(through EC aVb3).
14,30,35 Hence, aIIbb3 was identified as a primary
therapeutic target for I/R injury. There are already many aIIbb3
inhibitors on the market, including the chimeric monoclonal antibody
abciximab and a synthetic molecule, tirofiban; however, these may
be “too effective” at inhibiting platelet activity because associated
bleeding complications have limited their use as antiplatelet drugs.
Indeed, multiple groups have shown that aIIbb3 blockade has limited
or no effect on infarct size, whereas it actually increases
intracerebral hemorrhage and mortality.25,49,73 Thus, although aIIbb3
was once considered a promising target because of the significantly
increased risk of hemorrhagic transformation with aIIbb3 inhibitors,
other less potent drugs may be worth evaluating.
Platelet-secreted products have widespread effects
on I/R injury
Platelets have 3 main types of granules, a/d granules, and lysosomes,
which fuse with the plasma membrane to release their contents
following platelet activation (Figure 1).74 But before looking at the role
that some of these granule contents play in cerebral I/R injury, we will
first discuss the overall effect of decreasing platelet granules or their
secretion. In humans, gray platelet syndrome is a rare bleeding disorder
presenting with few to no a granules; this was replicated in mice by
deleting the neurobeachin-like 2 (Nbeal2) gene.75 Loss of Nbeal2 in
hematopoietic cells led to a 50% reduction in infarct size.75 Similarly,
Munc13-4, a protein product of the Unc13d gene, is involved in
secretion of a and d granules, and its absence leads to complete
abrogation of d-granule secretion and partial abrogation (;60%) of
a-granule secretion.76 The absence of Munc13-4 in Unc13d knockout
mice also revealed dramatic protection after tMCAO.76
Regarding the many constituents of platelet granules, several (like
ADP) are secondary platelet agonists and increase platelet activation in
a paracrine/autocrine manner, whereas others (like platelet factor 4
and b-thromboglobulin) are proinflammatory cytokines that serve to not
only recruit leukocytes, but also activate ECs. In addition to the EC/
platelet P-selectin interactions mentioned in "Platelet activation
following interaction with ECs and collagen," platelet P-selectin, which
is brought to the surface after platelet a-granule secretion, interacts
with neutrophil P-selectin glycoprotein ligand-1 to form PNAs and
to recruit neutrophils to the injury.14 Additionally, P-selectin may even
potentiate neutrophil extracellular trap formation in I/R, and target
neutrophil extracellular traps via DNase-improved outcomes in tMCAO
mice.77 Very recently, Denorme et al found that preventing platelet
necrosis (by targeting cyclophilin D, which is also important for PS
exposure, discussed in the next paragraph) not only reduced the
amount of P-selectin–positive platelets after tMCAO, but also
decreased PNAs and infarct size.78
Effects of PS-mediated thrombin generation and MP
release on I/R injury
Under resting conditions, anionic PS is on the inner leaflet of the
platelet membrane. Following platelet activation, PS is rapidly
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exposed via the activity of platelet scramblases and indirectly
facilitates the conversion of prothrombin to thrombin by recruiting
the coagulation proteins Xa and Va.79 As mentioned herein,
thrombin can both amplify platelet activation and increase edema
formation by inducing endothelial permeability; as such, inhibiting
platelet-mediated thrombin formation by decreasing PS exposure
would be expected to be protective in ischemic stroke. However,
infarct size was not reduced by a platelet-specific knockout of the
scramblase transmembrane protein 16F (which is important for PS
exposure), despite reduction in PS exposure, thrombin generation,
and thrombosis.79,80
Another phenomenon that occurs following platelet activation is
MP release. Because MPs bud off platelets (and other cell types,
but we are focusing on platelet-derived MPs), they often carry along
granule and cytosolic components. An additional mechanism by
which platelet MPs (PMPs) can interact with other cells is through
the transfer of microRNAs (miRs) (Figure 1).81,82 For example,
postischemia treatment with an mir-181a antagomir, which would
bind to and silence endogenous miR-181a (which is present in
platelets), reduced infarct size and improved functional recovery in
mice.83 Other miRs present in platelets that could also affect I/R
injury include miR-106b, miR-93, miR-223, and miR-656 (which
was shown to be significantly associated with stroke risk in
patients).82,84-87 Although no studies have yet been reported that
specifically studied the question of whether PMP-delivered miRs
can affect stroke size and subsequent behavioral recovery, this is
certainly an interesting line of study.
Platelet-derived factors may reduce
hemorrhagic transformation
Although an abundance of data establishes the role of platelets as
drivers of I/R injury after stroke, there is a small body of research that
supports the view that platelet activity is important, if not necessary, to
protect from I/R injury and aid in recovery following ischemic stroke.88
This is not surprising because, in addition to proinflammatory
cytokines, activated platelets can also release anti-inflammatory
cytokines like interleukin 10.89 Platelets also store both proangiogenic
and antiangiogenic factors that may regulate recovery.90 From
the research already presented, blockade of the platelet
integrin aIIbb3 showed limited/no effect on infarct size, while
increasing intracerebral hemorrhage and mortality following
tMCAO.25,49,73
Additionally, whereas the individual Nbeal2 and Unc13d knockouts
reduced I/R injury, when tMCAO was performed in Nbeal2/Unc13d
double knockout mice (DKO), half of the DKO mice died, as
opposed to no mortality in the WT mice; this high mortality rate was
reversed when WT platelets were transfused into DKO mice.91 The
increase in death was attributed to massive intracerebral hemor-
rhages.91 Intriguingly, of the DKO mice that did survive tMCAO,
they showed a statistically significant decrease in infarct volume,
just as the individual knockouts had.91 Therefore, some contents of
platelet granules are necessary to prevent hemorrhage and reduce
mortality after reperfusion. This is further supported by the recent
report that transfusion of resting, but not degranulated, platelets
ameliorated hemorrhage after tPA administration in tMCAO mice.92
Hence, the intracerebral hemorrhage seen in both of these settings
clearly demonstrates that some level of “normal” platelet function is
necessary to prevent exacerbation of I/R injury, especially for
preventing hemorrhages.
Furthermore, both platelet lysate and the delivery of PMPs
conferred protection from ischemic stroke.93-96 Regarding platelet
secreted/released factors that may help with central nervous
system repair after stroke, one of the prime candidates is brain-
derived neurotrophic factor (BDNF). First, activation of platelet
thrombin receptors (PAR1 and PAR4) led to release of BDNF from
platelets.97 Immunoelectron microscopy showed BDNF to be
stored in both a granules and in the cytosol of platelets, and it
was released within 5 minutes after thrombin stimulation.97 Use of
BDNF in stroke promoted repair by increasing neurogenesis,
oligodendrogenesis, and remyelination of injured white matter.98-100
It is important to note that although this pathway has not been
established in stroke models, it seems a worthy topic for further
investigation. In summary, not only can antiplatelet therapy at the






















Figure 2. Overview of the processes by which activated platelets mediate I/R injury. Following interaction with injured ECs, ROS, and factors released by I/R-injured
cells, platelets promote I/R injury by secreting granules and interacting with leukocytes. This includes enhancing leukocyte extravasation, oxidative burst, and capillary no-reflow
(which includes PNAs, fibrin deposition, and other cellular debris; only PNAs are shown for simplicity).
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injury after stroke, but subsequent treatment with neurotrophic
factors found in platelets, such as BDNF, could also help facilitate
neuronal repair and expedite recovery after ischemic stroke.
Concluding remarks
Platelets play a prominent role in reperfusion injury following
ischemia: going through the expanse of literature that clearly
demonstrates a plethora of ways in which platelets drive in-
flammation after I/R, to a small but intriguing body of research that
suggests platelets may also promote recovery after ischemic stroke.
Thus, by now, it is clear that platelets are not just involved in the clot
that initiates ischemic stroke, but, rather, platelets are major players
in the progression of I/R injury. Upon reperfusion, platelets can
respond to I/R-generated agonists such as ROS, HMGB1, and
VWF. In addition to molecules secreted by injured cells, platelets
can also bind to and be activated by injured endothelium and
subendothelial matrix components exposed after I/R injury. These
multitudinous mechanisms converge on platelet activation, which
includes platelet granule secretion, PS exposure, and PMP release.
Ultimately, these lead to EC activation, leukocyte recruitment, and
capillary no-reflow, which worsen tissue death and expand the size
of the infarct (Figure 2).
Once platelets are activated, the most promising targets to treat I/R
injury are those that prevent platelet adhesion and activation, not
those that inhibit downstream effects such as platelet aggregation
or thrombin generation.25,49,73,79 This is likely because rapid
secretion of platelet granule contents seems to be the most critical
mechanism by which platelets exacerbate I/R injury after stroke.75,76
These platelet-secreted products cannot only activate ECs and
induce vascular permeability, but they can also potently recruit
and induce leukocytes.32 Because complete blockade of granule
secretion can lead to hemorrhage, the better and more efficacious
strategy seems to be in attenuating I/R-mediated platelet activation
in the first place.91 But, although reducing platelet activity is
a promising approach to decrease cell death and functional deficits,
it is important to keep in mind that platelet integrin function and
granule secretion should be at least partially intact to prevent
hemorrhagic transformation. In summary, although thrombolytic
therapies have improved the functional outcome of stroke patients
compared with patients without reperfusion, many stroke patients
suffer from lifelong disabilities, reaffirming Hippocrates’ point
even today.2 Thus, in order to achieve the full clinical benefit of
reperfusion, identifying new targets for treating I/R injury is essential
to decreasing stroke-related death and disability.
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